Practical Geriatrics ›› 2024, Vol. 38 ›› Issue (6): 587-591.doi: 10.3969/j.issn.1003-9198.2024.06.011

Previous Articles     Next Articles

Effect of pancreatic kallidinogenase on mild cognitive impairment in elderly patients with type 2 diabetes mellitus

SHI Wen, ZHU Ping, ZHOU Jie, YAN Ting, HUANG Yujie, YAN Yan   

  1. Department of Endocrinology, the Affiliated Huai’an Hospital of Jiangsu College of Nursing (Huai’an Cancer Hospital), Huai’an 223200, China (SHI Wen, ZHOU Jie, YAN Ting, HUANG Yujie, YAN Yan);
    Department of Endocrinology, the Affiliated Chuzhou Hospital of Traditional Chinese Medicine of Jiangsu College of Nursing, Huai’an 223200, China (ZHU Ping)
  • Received:2023-08-04 Online:2024-06-20 Published:2024-06-19
  • Contact: ZHU Ping, Email: 18360757374@163.com

Abstract: Objective To explore the efficacy of pancreatic kallidinogenase in the elderly patients with type 2 diabetes mellitus (T2DM) combined with mild cognitive impairment (MCI). Methods Ninety-six elderly T2DM patients with MCI admitted to our hospital from June 2021 to June 2023 were enrolled in this study, and they were divided into the control group and the observation group by random number table method, with 48 cases in each group. The control group received routine treatment (metformin combined with donepezil hydrochloride). The observation group received pancreatic kallidinogenase treatment on the basis of the control group. The levels of blood glucose control, cognitive function, inflammatory factors, renal function, islet function and medication safety were compared between the two groups. Results After treatment, the levels of fasting blood glucose and glycosylated hemoglobin in both groups were lower than those before treatment (P<0.05), but there were no statistical differences between the two groups (P>0.05). After treatment, the levels of insulin resistance index (HOMA-IR), S100β protein, tumor necrosis factor-α, interleukin-6, serum creatinine and cystatin C in both groups were lower than those before treatment, and the levels of fasting C-peptide and insulin secretion index (HOMA-β), and the score of Montreal Cognitive Assessment (MoCA) in both groups were higher than those before treatment, especially in the observation group (P<0.05). There was no statistically significant difference in the total incidence rate of adverse reactions between the two groups (P>0.05). Conclusions Pancreatic kallidinogenase in the clinical treatment of elderly patients with T2DM and MCI can effectively improve the cognitive function, renal function and islet function, reduce the level of inflammation, and the medication is safe and controllable.

Key words: type 2 diabetes mellitus, mild cognitive impairment, pancreatic kininogenase, inflammation level, aged

CLC Number: